Xilio Therapeutics (XLO) Cash & Equivalents (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Cash & Equivalents data on file, last reported at $150.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 68.74% year-over-year to $150.3 million; the trailing twelve-month figure through Mar 2026 stood at $150.3 million (up 68.74% YoY), and the FY2025 full-year result was $137.5 million, up 148.74% from the prior year.
• Cash & Equivalents grew to $150.3 million in Q1 2026, from $137.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $177.0 million in Q1 2022 to a low of $34.0 million in Q1 2024.
• A 5-year average of $99.8 million and a median of $93.3 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 63.57% in 2024 and jumped 162.13% in 2025, its largest moves.
• Tracing XLO's Cash & Equivalents over 5 years: stood at $120.4 million in 2022, then slumped by 62.87% to $44.7 million in 2023, then climbed by 23.68% to $55.3 million in 2024, then surged by 148.74% to $137.5 million in 2025, then gained by 9.28% to $150.3 million in 2026.
• Business Quant data shows XLO's Cash & Equivalents at $150.3 million in Q1 2026, $137.5 million in Q4 2025, and $103.8 million in Q3 2025.